| |
| |
|
| Insider
Information: |
Taub Rebecca |
| Relationship: |
|
| City: |
San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
616,499 |
|
|
Indirect Shares
|
655,540 |
|
|
| Direct
Value |
$94,209,545 |
|
|
|
Indirect Value
|
$134,549,585 |
|
|
| Total
Shares |
1,272,039 |
|
|
| Total
Value |
$228,759,130 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Corautus Genetics Inc |
VEGF |
SVP, Research & Develo... |
2008-12-17 |
157,500 |
2008-12-05 |
0 |
Premium* |
|
|
Madrigal Pharmaceuticals Inc |
MDGL |
|
2024-04-08 |
458,999 |
2024-04-08 |
655,540 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
17 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MDGL |
Madrigal Pharmaceuticals ... |
Pres., R&D, and CMO |
• • – |
2024-04-08 |
4 |
AS |
$243.25 |
$658,258 |
D/D |
(2,676) |
458,999 |
0 |
% |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Pres., R&D, and CMO |
• • – |
2024-04-08 |
4 |
OE |
$9.45 |
$25,288 |
D/D |
2,676 |
461,675 |
0 |
- |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Pres., R&D, and CMO |
• • – |
2024-04-05 |
4 |
AS |
$240.11 |
$6,693,790 |
D/D |
(27,506) |
458,999 |
0 |
% |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Pres., R&D, and CMO |
• • – |
2024-04-05 |
4 |
OE |
$9.45 |
$259,932 |
D/D |
27,506 |
486,505 |
0 |
- |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Pres., R&D, and CMO |
• • – |
2024-04-04 |
4 |
AS |
$240.88 |
$4,502,823 |
D/D |
(18,537) |
458,999 |
0 |
% |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Pres., R&D, and CMO |
• • – |
2024-04-04 |
4 |
OE |
$9.45 |
$175,175 |
D/D |
18,537 |
477,536 |
0 |
- |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Pres., R&D, and CMO |
• • – |
2024-04-03 |
4 |
AS |
$242.00 |
$6,825,976 |
D/D |
(27,845) |
458,999 |
0 |
% |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Pres., R&D, and CMO |
• • – |
2024-04-03 |
4 |
OE |
$9.45 |
$263,135 |
D/D |
27,845 |
486,844 |
0 |
- |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Pres., R&D, and CMO |
• • – |
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
5,786 |
20,787 |
0 |
- |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Pres., R&D, and CMO |
• • – |
2024-01-16 |
4 |
D |
$243.92 |
$377,100 |
D/D |
(1,546) |
15,001 |
0 |
- |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Pres., R&D, and CMO |
• • – |
2023-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
20,001 |
20,001 |
0 |
- |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Chief Medical Officer, EVP R&D |
• • – |
2018-06-11 |
4 |
S |
$287.46 |
$21,135,784 |
I/I |
(73,526) |
655,540 |
0 |
- |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Chief Medical Officer, EVP R&D |
• • • |
2016-07-22 |
4/A |
A |
$0.00 |
$0 |
D/D |
30,626 |
434,758 |
0 |
- |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Chief Medical Officer, EVP R&D |
• • • |
2016-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
432,872 |
432,872 |
0 |
- |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Chief Medical Officer, EVP R&D |
• • • |
2016-07-22 |
4 |
A |
$0.00 |
$0 |
I/I |
729,066 |
729,066 |
0 |
- |
|
| VEGF |
Corautus Genetics Inc |
SVP, Research & Development |
• – – |
2008-12-17 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
157,500 |
0 |
- |
|
| VEGF |
Corautus Genetics Inc |
SVP, Research & Development |
• – – |
2008-12-05 |
4 |
B |
$0.30 |
$9,750 |
D/D |
32,500 |
32,500 |
2.74 |
- |
|
17 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
